ポスターのタイトル

  • Agency for Science, Technology and Research (A*STAR): A*STAR Peptide Engineering Programme (PEP) Technologies and Capability
  • Angelini S.p.A.: Design, Synthesis, and Optimization of Novel Dual Bacterial Topoisomerase Type IIA Inhibitors
  • AssayQuant Technologies, Inc.: CSox-Based Sensors for Continuous, Homogeneous and Quantitative Monitoring of Protein Kinase and Phosphatase Activity
  • BellBrook Labs: Targeting Cyclic GAMP Synthase for Interferon-Driven Autoimmune Diseases
  • BellBrook Labs: The Transcreener® ADP Assay: A Universal Kinase Assay for HTS and Lead Optimization
  • BIOCAD: Development of New Next-In-Class Selective BTK BCD-141 Series Inhibitors
  • Biodesy, Inc.: Identifying Allosteric Modulators of KRas Using Second Harmonic Generation
  • BioSolveIT, Inc.: Exploring 647,141,139 Molecules Available On Demand
  • Boryung Pharmaceticals Co. Ltd.: Identification of BR101459, the First Non-TZD PPAR? Full Agonist for the Treatment of Type 2 Diabetes and Its Diminishing Potential in Adverse Effect of TZDs
  • Boston University: Development and Validation of Macrocycle Specific Molecular Descriptors and Their Validation by Machine Learning
  • BPS Bioscience, Inc.: Methods for Drug Discovery Through Biochemical and Cell Based Assays for Immunotherapy Checkpoint Activators and Inhibitors
  • Bristol-Myers Squibb: 4-Aminopyrrolo[1,2-b]Pyridazine-3-Carboxamide as Janus Kinase (JAK) Inhibitors: Discovery of Potent Dual JAK1/JAK3 Inhibitors Using 3-Azabicyclo[3.3.0]Octane as 4-Amino Substituent
  • ChemBridge Corporation: Synthetic Macrocycle Library with Potential to Find Hits for CNS Drug Discovery Programs
  • ChemDiv, Inc.: Library of sp3-Enriched a-Helix and b-Turn Mimetics: Design and Synthesis
  • ChemPartner, Inc.: Parallel FBDD Approaches Targeting Nicotinamide Phospho-Ribosyl-Transferase (NAMPT)
  • China Pharmaceutical University: The New Plant Parinari kerstingii Engl.: Anti-Inflammatory Activities and Toxicity Study
  • Chinese Academy of Medical Sciences: Development of a Selective S1P1 Receptor Agonist, IMMH002, as a Potential Therapeutic Agent for Psoriasis
  • Chinese Academy of Medical Sciences: XH010, a Novel PI3K/mTOR Dual Inhibitor for Treatment of Human Cancers
  • Chinese Academy of Medical Sciences: STEAP3 Regulated Ion Iron Changes in Liver Cancer
  • Chinese Academy of Sciences: In-Depth Proteome Coverage by Improving Efficiency for Membrane Proteome Analysis
  • Chung-Ang University: Discovery of Reversible and Mutant Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
  • Cresset: Deciphering Kinase SAR Using Electrostatics
  • Daegu Gyeongbuk Institute of Science and Technology (DGIST): Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) Using Molecular Dynamics Simulations
  • Damanhour University: Discovery of New Indomethacin-Based Analogs with Potentially Selective Cyclooxygenase-2 Inhibition and Observed Diminishing to PGE2 Activities
  • Dankook University: Molecular Dynamics Simulations of E2 Protein Cage
  • Domainex Ltd.: Fragment Screening Against the Lysine Methyltransferase G9a Using Microscale Thermophoresis
  • Edelris SAS: Towards the Discovery of BAY-850, a Selective and Cell-Active ATAD2 Bromodomain Inhibitor
  • Enamine Ltd.: Novel Specific Covalent Warheads for Fragment Library Synthesis: Functionalized Diazirines and Novel Amino Boronic Acids
  • Eurofins DiscoverX: Modifying Standard Assay for Assessing Allosteric Activity
  • Eurofins Pharma Discovery Services: Binding and Functional Analysis - Complementary Approaches in Safety Pharmacology
  • Ewha Womans University: Stepwise Structure-Based Virtual Screening for the Discovery of Protein-Protein Interaction Inhibitors of Ataxin-1 and Capicua
  • Fidelta Ltd.: Macrolide Inspired Macrocycles as Effective Disruptors of the IL-17A/IL-17RA Interaction
  • Florida A&M University: Potential GPCR Ligands for Schizophrenia
  • GE Healthcare: Development of a Protein-Protein Interaction Inhibition Assay Using Biacore™ 8K
  • GE Healthcare: Why Sensitivity Matters: Reliable Hit Characterization for Challenging Targets Using High Sensitivity SPR Systems
  • GE Healthcare: Binding Kinetics by Surface Plasmon Resonance: Insight into Structure-Kinetics/Thermodynamics Relationships
  • Genomics Institute of the Novartis Research Foundation: Discovery of Encorafenib, a Potent, Selective RAF Kinase Inhibitor for Treatment of BRAFV600E-Positive Melanoma
  • Gyros Protein Technologies: Rapid Picomolar Affinity Measurements Using Gyrolab Automated Immunoassay Systems
  • Hypha Discovery Ltd.: Microbial Biotransformation as a Tool to Exploit the Potential of Drug Metabolites for Lead Optimization
  • Key Organics Ltd.: Building a Diverse and Experimentally-Curated Fragment Library
  • Key Organics Ltd.: New BIONET Compounds for CNS Diseases
  • Korea Institute of Science and Technology (KIST): Structure-Activity Relationships of Baulamycin A Derivatives
  • Korea Research Institute of Chemical Technology (KRICT): Design and Synthesis of DYRK1B Inhibitors
  • Life Chemicals, Inc.: Novel Fragments Libraries from Life Chemicals
  • Life Chemicals, Inc.: Small Molecule Libraries for Early Drug Discovery from Life Chemicals, Inc.
  • LifeArc: Fragment-Based Discovery of Inhibitors of the CSF1R:IL-34 Interaction Targeting Neuroinflammation in Alzheimer's Disease
  • Masaryk University: Selective Stabilization of G-Quadruplex Structures by Quaternary Benzophenantridine Alkaloids
  • Mayo Clinic: Assemblage of Parkin Conformational States Coupled with Fragment-Based Structure-Guided Drug Discovery for Novel Activators
  • Medical & Biological Laboratories, Co., Ltd.: Fluoppi: A Cell Based Assay Harnessing Intracellular Phase Transitions to Visualize Activities of Protein-Protein Interaction Modulators (PPIMs)
  • Merck Sharp & Dohme (MSD): Exploring Stapled Peptide Permeability Using p53 as a Model System
  • Nanyang Technological University: Structural Insights into Designing Selective ATP-Competitive Inhibitors of Vaccinia-Related Kinase 1 (VRK1), a Mitotic Protein Kinase
  • National Cancer Center: A Secondary RET Mutation in the Activation Loop Conferring Resistance to Vandetanib Through Allosteric Effects
  • Osaka Dental University: Searching for the Pharmaceutical use of PTH Receptor in Japanese Quail
  • Prestwick Chemical PC SAS: The Prestwick Drug-Fragment Library: An Innovative Tool for FBDD
  • Promega Corporation: Exploring Kinetic Selectivity for Kinase Inhibitors in Live Cells Using BRET
  • Promega Corporation: Quantitate Kinase Inhibitor Potency and Selectivity in Live Cells Using BRET
  • Promega Corporation: Monitoring Functional Mechanisms of Protein Degradation in Living Cells
  • Purdue University: Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors
  • Redshift BioAnalytics: Enhanced Protein Structural Characterization using Microfluidic Modulation Spectroscopy (MMS)
  • Rutgers, The State University of New Jersey: Structure-Based Discovery of Novel Sigma 1 Receptor Antagonists with Antinociceptive Efficacy in Rats
  • Sanford Burnham Prebys Medical Discovery Institute: Structural Basis for Potency of SMAC Mimetic Antagonists for Inhibitor of Apoptosis Protein ML-IAP
  • Seoul National University: A Cell Penetrating Peptide that Helps Deliver Cyclosporine A in a Nanomolar Concentration as a Component of a New Formulation for Dry Eye Syndrome Therapy
  • Singapore-MIT Alliance for Research and Technology (SMART) Centre: Targeting the Ribonucleome for Antibiotic Development
  • South Dakota State University: Development of a High-Performance Liquid Chromatography Method for the Analysis of Next-Generation Cyanide Antidotes, 3-Mercaptopyruvate in Plasma
  • Sungkyunkwan University: Site-Selective Chemical Conjugation onto Antibodies
  • Taros Chemicals GmbH & Co. KG: European Lead Factory - Collective Intelligence Boosting European Drug Discovery with Public Compound Collection
  • University of California, Riverside: Enthalpy-Based Screening and Enthalpy-Entropy Compensation Analysis for the Design of Potent and Selective IAPs Inhibitors
  • University of California, Riverside: Design, Synthesis and Evaluation of Novel, Potent Irreversible XIAP Inhibitors with Superior Cellular Activity in Refractory Tumors
  • University of California, San Diego: DYRK2, a Novel Therapeutic Target in 26S Proteasome Dependent Neoplastic Malignancies
  • University of California, Santa Cruz: CycLS: Accurate, Whole-Library Sequencing of Cyclic Peptides Using Tandem Mass Spectrometry
  • University of California, Santa Cruz: Membrane-Permeable Lariat Peptides
  • University of California, Santa Cruz: Improving Upon Nature: A Medicinal Chemistry Optimization of Cordyheptapeptide A and B
  • University of California, Santa Cruz: Synthetic Cyclic Peptomers as Virulence Blockers that Suppress Pathogenicity of Antibiotic Resistant Bacteria
  • University of Eastern Finland: Molecular Docking and Hydration Site Approaches in the Discovery of Cyclin G Associated Kinase of Inhibitors
  • University of Florida: The Evolution of Apratoxins: Total Synthesis of Natural Products and Analogues with Improved Anticancer Activity
  • University of Groningen: Drug Discovery at the Speed of Sound
  • University of Hong Kong: Discovering Small Compound Modulators for Secretin Receptor
  • University of Pittsburgh: Ubiquitin Carboxyl-Terminal Hydrolase-L5 Inhibitor Diminishes TGF?-1 Signaling and Ameliorates Pulmonary Fibrosis
  • University of South Africa: Synthesis, Cytotoxicity and Molecular Docking of the 4-Aminoquinazoline Appended Benzofuran Hybrids as Epidermal Growth Factor Receptor Inhibitors
  • University of Southern California: Structure-Based Design of Novel Non-Morphinan Bi-Functional Small Molecule Analgesics with Reduced Liabilities
  • University of Southern California: Structure Based Screening for P2Y2 Receptor Antagonists
  • University of Tokyo: Maturing a Macrocyclic Peptide into a Drug Candidate Using RaPID Scanning
  • University of Toronto: Overcoming the Blood Brain Barrier with Focused Ultrasound Therapy and Gold Nanoparticles
  • University of Washington: Saturation Mutagenesis Comprehensively Identifies Resistance Mutations to Conformation-Selective Kinase Inhibitors
  • Uppsala University: Target Engagement-Mediated Amplification (TEMA): Selective Monitoring of Drug-Target Interactions
  • Uppsala University: The Cellular Thermal Shift Assay (CETSA) with Readout by PEA - Sensitive Measurement of Cellular Drug-Protein Binding
  • Virginia Commonwealth University: Development of Mu Opioid Receptor Selective Modulators as Novel Therapeutics for Substance Abuse and Addiction
  • Weizmann Institute of Science: Quantitative Analysis of Protein-Protein Interactions In Vivo to Achieve Proteome Wide Information

ポスター発表

ポスター発表で参加登録費が50ドル割引に  

シンポジウムとカンファレンスそれぞれのプログラムに即したポスターセッション

 

Cambridge Healthtech Institute (CHI) では、知名度を高めていただくため、ポスターセッションのなかで研究成果を発表するようお勧めしています。ポスター発表をご希望の方は、2018年2月23日までに要旨を提出して承認を受けていただくとともに、参加登録費を全額お支払いください。ポスターボードを確保し、要旨を学会資料に掲載いたします。

参加登録は、オンラインでも、電話やファックス、郵送でも行うことができます。ポスター発表をご希望の方は、参加登録時にその旨お知らせください。登録手続き完了後、各参加者専用のリンク、およびオンラインツールを使って要旨を提出するための手順を記載した電子メールをお送りします。詳細は下記をご覧ください。

ポスター発表をお勧めする理由

  • 大手製薬会社、バイオテクノロジー企業、研究機関、政府機関などの幹部たちの前で研究成果を披露することができます。
  • 参加登録費が50ドル割引になります。
  • ポスター発表のコンテストに自動的にエントリーされます(詳細は下記をご覧ください)。
  • 学会資料にポスター発表の要旨が掲載されます。


ポスター発表コンテストの詳細 (メインカンファレンス)
•         ポスター発表の要旨は、必ず所定の期限までに提出してください。
•         下記の基準に基づき、最優秀ポスター賞の受賞者2名が選ばれます。
•         賞金は、メインカンファレンス最終日 (シンポジウムは含みません) の4月5日(木)に展示会ホールで授与されます。受賞者が不在の場合には、小切手を郵送いたします。

第1段階の選考は、提出された要旨を審査するという形で行われ、この学会を担当するCHIのディレクターと科学諮問委員会の委員が、以下の基準に基づいて審査します。
•         要旨の明確さ
•         データの新規性
•         創薬にとっての重要性

最終段階の選考は、以下の基準に基づき、会場内で行われます。
•         ポスターの外観上の品質と視覚的な明瞭さ
•         ポスターに関する口頭での説明の明瞭さと魅力

2017 Poster Competition Winners

Dr. Simon Hurst, CEO of Sygnature Discovery, sponsor of 2017 poster competition, awarding the winners:

Bin Zhao, Vanderbilt University
Discovery and Biological Characterization of Potent Myeloid Cell Leukemia-1 Inhibitors

Alix Boucharlat, Institut Pasteur
Hydrocarbon-Stapled Peptide Inhibitors of NEMO as Potential Anti-Inflammatory and Anti-Cancer Drugs



CAMBRIDGE HEALTHTECH INSTITUTE IS PROUD TO SUPPORT AND RECOGNIZE THE SCIENTISTS OF TOMORROW!

**Full time graduate students and PhD candidates qualify for the student rate. Students are encouraged to present a research poster and receive an additional $150 discount off their registration fee and will be recognized as a Student Fellow of the event.


SUBMIT A POSTER WHEN REGISTERING AND BECOME A STUDENT FELLOW!

  • Receive a poster presentation slot and a savings off your registration fee
  • Present your research poster to an international delegation representing leaders from top pharmaceutical, biotech, academic and government institutions
  • Meet face-to-face with potential employers and contacts to further your research and form collaborations
  • Be entered in the Poster Competition - with cash prizes!
  • Student Fellows must register and submit a poster abstract by February 23, 2018.


NOTE: 

ポスター発表の場は、1つのポスターセッションに限定されます。カンファレンスプログラムのポスターは、メインカンファレンスのトピックに即したもの、シンポジウムのポスターは、選択したシンポジウムのトピックに即したものでなければなりません。

ポスターは、選択したプログラムの会期中のみ掲示されます。

所定の期日までに提出されなかったポスターも、スペースに空きがある場合には受付可能ですが、学会の資料には掲載されません。

 

 

カンファレンスプログラムのポスターセッションで発表を行うには、カンファレンスプログラムへの参加登録が必要です。またシンポジウムのポスターセッションで発表を行うには、シンポジウムへの参加登録が必要です。

* ポスターのタイトルと要旨がCHIの発行する各種のマーケティング資料や商品に掲載される場合があります。
** ポスター発表の割引が適用されるのは、参加登録された方1名につき1回のみです。

ご注意:ポスターは縦方向で、サイズは横36インチ (3 フィート) ×48インチ (4フィート) までとなります。 

ポスター展示:
ポスター展示についてはお手数ですが会議参加お申し込み時にご連絡事項にご記入頂くか、お問い合わせより別途お申し込み頂ければ幸いに存じます。